| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
BRIEF REVIEWS |
* Cancer Epigenetics Laboratory, Molecular Pathology Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain; and
Department of Medicine, University of Michigan, Ann Arbor, MI 48109
Systemic lupus erythematosus (SLE) is an archetypical systemic, autoimmune inflammatory disease characterized by the production of autoantibodies to multiple nuclear Ags. Apoptotic defects and impaired removal of apoptotic cells contribute to an overload of autoantigens that become available to initiate an autoimmune response. Besides the well-recognized genetic susceptibility to SLE, epigenetic factors are important in the onset of the disease, as even monozygotic twins are usually discordant for the disease. Changes in DNA methylation and histone modifications, the major epigenetic marks, are a hallmark in genes that undergo epigenetic deregulation in disease. In SLE, global and gene-specific DNA methylation changes have been demonstrated to occur. Moreover, histone deacetylase inhibitors reverse the skewed expression of multiple genes involved in SLE. In the present study, we discuss the implications of epigenetic alterations in the development and progression of SLE and how epigenetic drugs constitute a promising source of therapy to treat this disease.
This article has been cited by other articles:
|
|
 |
|
  H. Long, W. Huang, H. Yin, S. Zhao, M. Zhao, and Q. Lu Abnormal expression pattern of histone demethylases in CD4 + T cells of MRL/lpr lupus-like mice Lupus, December 1, 2009; 18(14): 1327 - 1328. [PDF]
|
|
|
|
|
|
M. Blank, Y. Shoenfeld, and A. Perl Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus Lupus, November 1, 2009; 18(13): 1136 - 1143. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Garaud, C. Le Dantec, S. Jousse-Joulin, C. Hanrotel-Saliou, A. Saraux, R. A. Mageed, P. Youinou, and Y. Renaudineau IL-6 Modulates CD5 Expression in B Cells from Patients with Lupus by Regulating DNA Methylation J. Immunol., May 1, 2009; 182(9): 5623 - 5632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Matouk and P. A. Marsden Epigenetic Regulation of Vascular Endothelial Gene Expression Circ. Res., April 25, 2008; 102(8): 873 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wen, M. A. Schaller, Y. Dou, C. M. Hogaboam, and S. L. Kunkel Dendritic cells at the interface of innate and acquired immunity: the role for epigenetic changes J. Leukoc. Biol., March 1, 2008; 83(3): 439 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wen, Y. Dou, C. M. Hogaboam, and S. L. Kunkel Epigenetic regulation of dendritic cell-derived interleukin-12 facilitates immunosuppression after a severe innate immune response Blood, February 15, 2008; 111(4): 1797 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. K. Wen, W. Xu, L. Xu, Q. H. Cao, Y. Wang, Y. W. Chu, and S. D. Xiong DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice Rheumatology, December 1, 2007; 46(12): 1796 - 1803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Burzynski, S. Duriagin, M. Mostowska, M. Wudarski, H. Chwalinska-Sadowska, and P.P. Jagodzinski MTR 2756 A > G polymorphism is associated with the risk of systemic lupus erythematosus in the Polish population Lupus, June 1, 2007; 16(6): 450 - 454. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Mazari, M. Ouarzane, and M. Zouali Subversion of B lymphocyte tolerance by hydralazine, a potential mechanism for drug-induced lupus PNAS, April 10, 2007; 104(15): 6317 - 6322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Deane and S. Bolland Nucleic Acid-Sensing TLRs as Modifiers of Autoimmunity J. Immunol., November 15, 2006; 177(10): 6573 - 6578. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
